Profiel
Charlotta Gauffin is currently Chief Scientific Officer at Dicot Pharma AB since 2022.
Former positions include Head-Clinical Trial Management at LIDDS AB from 2019 to 2022, and Manager-Clinical Project & Program Director at Medivir AB, Biovitrum AB, and Galderma Holding AB. Education includes graduate and doctorate degrees from the University of Uppsala.
Actieve functies van Charlotta Gauffin
| Bedrijven | Functie | Begin |
|---|---|---|
| DICOT PHARMA AB | Hoofd Techniek/Wetenschap/O&O | 11-07-2022 |
Eerdere bekende functies van Charlotta Gauffin
| Bedrijven | Functie | Einde |
|---|---|---|
| LIDDS AB | Hoofd Techniek/Wetenschap/O&O | 01-07-2022 |
Galderma Holding AB | Hoofd Techniek/Wetenschap/O&O | - |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Hoofd Techniek/Wetenschap/O&O | - |
| MEDIVIR AB | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Charlotta Gauffin
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
Medivir AB
Medivir AB Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Commercial Services |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LIDDS AB
LIDDS AB Pharmaceuticals: MajorHealth Technology Focuses on the development of treatment alternatives and hormonal therapy for prostate cancer | Health Technology |
Galderma Holding AB | |
Dicot Pharma AB
Dicot Pharma AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs to treat erectile failure | Health Technology |
















